| Literature DB >> 26410308 |
Natalie S Ryan1, Geert-Jan Biessels2, Lois Kim3, Jennifer M Nicholas4, Philip A Barber5, Phoebe Walsh6, Priya Gami6, Huw R Morris7, António J Bastos-Leite8, Jonathan M Schott5, Jon Beck9, Simon Mead9, Lucia Chavez-Gutierrez10, Bart de Strooper10, Martin N Rossor5, Tamas Revesz6, Tammaryn Lashley6, Nick C Fox5.
Abstract
Familial Alzheimer's disease (FAD) treatment trials raise interest in the variable occurrence of cerebral amyloid angiopathy (CAA); an emerging important factor in amyloid-modifying therapy. Previous pathological studies reported particularly severe CAA with postcodon 200 PSEN1 mutations and amyloid beta coding domain APP mutations. As CAA may manifest as white matter hyperintensities (WMH) on magnetic resonance imaging, particularly posteriorly, we investigated WMH in 52 symptomatic FAD patients for associations with mutation position. WMH were visually rated in 39 PSEN1 (18 precodon 200); 13 APP mutation carriers and 25 healthy controls. Ten PSEN1 mutation carriers (5 precodon 200) had postmortem examination. Increased WMH were observed in the PSEN1 postcodon 200 group and in the single APP patient with an amyloid beta coding domain (p.Ala692Gly, Flemish) mutation. WMH burden on MRI correlated with severity of CAA and cotton wool plaques in several areas. The precodon 200 group had younger ages at onset, decreased axonal density and/or integrity, and a greater T-lymphocytic response in occipital deep white matter. Mutation site contributes to the phenotypic and pathological heterogeneity witnessed in FAD.Entities:
Keywords: Amyloid precursor protein (APP); Cerebral amyloid angiopathy; Familial Alzheimer's disease; Presenilin 1 (PSEN1, PS1); White matter hyperintensities
Mesh:
Substances:
Year: 2015 PMID: 26410308 DOI: 10.1016/j.neurobiolaging.2015.08.026
Source DB: PubMed Journal: Neurobiol Aging ISSN: 0197-4580 Impact factor: 4.673